138 related articles for article (PubMed ID: 37451912)
1. Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects.
He X; Liu G; Chen X; Wang Y; Liu R; Wang C; Huang Y; Shen J; Jia Y
Clin Ther; 2023 Jul; 45(7):655-661. PubMed ID: 37451912
[TBL] [Abstract][Full Text] [Related]
2. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
[TBL] [Abstract][Full Text] [Related]
3. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
[TBL] [Abstract][Full Text] [Related]
4. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers.
Chen ZD; Chen Q; Zhu YT; Zhang YF; Zhan Y; Chen XF; Liang X; Jia JY; Yu C; Liu HY; Zou JJ; Liu YM; Zhong DF
Clin Ther; 2021 Sep; 43(9):e264-e273. PubMed ID: 34366153
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers.
Huang Y; Liu R; Wang Y; Liu G; Wang C; Chen X; Jia Y; Shen J
Clin Ther; 2022 Jul; 44(7):945-956. PubMed ID: 35778161
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
Wang L; Wu C; Shen L; Liu H; Chen Y; Liu F; Wang Y; Yang J
Xenobiotica; 2016 Aug; 46(8):703-8. PubMed ID: 26608671
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers.
Chen Q; Yu C; Wu Q; Song R; Liu Y; Feng S; Yu C; Jia J
Drug Des Devel Ther; 2024; 18():1855-1864. PubMed ID: 38828023
[TBL] [Abstract][Full Text] [Related]
8. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
Kim YK; Hwang JG; Park MK
Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
[TBL] [Abstract][Full Text] [Related]
9. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
10. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
Yong X; Wen A; Liu X; Liu H; Liu YP; Li N; Hu T; Chen Y; Wang M; Wang L; Dai X; Huang J; Li J; Shen H
Clin Drug Investig; 2016 Mar; 36(3):195-202. PubMed ID: 26692004
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects.
Sun F; Liu Y; Li T; Lin P; Jiang X; Li X; Wang C; Gao X; Ma Y; Fu Y; Cao Y
BMC Pharmacol Toxicol; 2023 Feb; 24(1):7. PubMed ID: 36737825
[TBL] [Abstract][Full Text] [Related]
13. Effects of Food and Multiple-dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained-release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers.
Liu Y; Huyan X; Zhang Q; Qing H; Zhang Q; Wang X; Li Y; Liu Z; Hu W
Clin Pharmacol Drug Dev; 2023 Apr; 12(4):376-384. PubMed ID: 36408821
[TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers.
Nakamura T; Shimizu H; Kawaguchi A
Clin Ther; 2020 Nov; 42(11):2171-2183.e4. PubMed ID: 33153727
[TBL] [Abstract][Full Text] [Related]
15. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers.
Chu N; Xu H; Wang G; Wang J; Chen W; Yuan F; Yang M; Li X
Clin Ther; 2015 Feb; 37(2):462-72. PubMed ID: 25465944
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin.
Yan JH; Meyers D; Lee Z; Danis K; Neelakantham S; Majumdar T; Rebello S; Sunkara G; Chen J
J Clin Pharmacol; 2014 Jul; 54(7):800-8. PubMed ID: 24619917
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
[TBL] [Abstract][Full Text] [Related]
19. A Pharmacokinetic Drug-Drug Interactions Study between Entecavir and Hydronidone, a Potential Novel Antifibrotic Small Molecule, in Healthy Male Volunteers.
Zhang R; Li P; Guo P; Zhou J; Wan J; Yang C; Zhou J; Liu Y; Shi S
Adv Ther; 2023 Feb; 40(2):658-670. PubMed ID: 36477590
[TBL] [Abstract][Full Text] [Related]
20. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
